Abstract Objective To investigate the effect of baicalin on the behavioral characteristics of rats with attention deficit hyperactivity disorder (ADHD), and to provide a basis for further research on baicalin in the treatment of ADHD.Methods A total of 40 SHR rats were randomly divided into model group, methylphenidate hydrochloride (MPH) group, and low-, medium-, and high-dose baicalin groups, with 8 rats in each group. Eight WKY rats were selected as normal control group. The rats in the MPH group (0.07 mg/mL) and the low- (3.33 mg/mL), medium- (6.67 mg/mL), and high-dose (10 mg/mL) baicalin groups were given the corresponding drugs (1.5 mL/100 g) by gavage twice a day, and those in the normal control group and the model group were given an equal volume of normal saline by gavage twice a day. The course of treatment was 4 weeks for all groups. The open field test was performed to observe total moving distance and average moving speed on day 0 of experiment and at 7, 14, 21, and 28 days after gavage and to evaluate the control effects of drugs on hyperactivity and impulsive behavior. The Morris water maze test was used to observe the latency, time spent in the target quadrant, and number of platform crossings and to evaluate the effects of drugs on attention.Results The open field test showed that the model group and the drug treatment groups had a significantly longer total moving distance and a significantly higher average moving speed than the normal control group on day 0 (P < 0.05). On day 7, the MPH group had significant reductions in total moving distance and average moving speed compared with the model group (P < 0.05). On day 14, the MPH group and the high-dose baicalin group had significant reductions in total moving distance and average moving speed compared with the model group (P < 0.05). The data on days 21 and 28 showed that compared with the model group, the low-, medium-, and high-dose baicalin groups had gradual reductions in total moving distance and average moving speed (P < 0.05). The water maze test showed that compared with the model group, the MPH group and the medium- and high-dose baicalin groups had a significantly longer time spent in the target quadrant (P < 0.05), and the MPH group and the high-dose baicalin group had a significantly higher proportion of the moving distance in the target quadrant in total moving distance (P < 0.05). The high-dose baicalin group had the highest number of platform crossings among all groups (P < 0.05).Conclusions Both baicalin and MPH can regulate the motor ability and learning and memory abilities of SHR rats with ADHD and thus control the core symptoms of ADHD, i.e., hyperactivity, impulsive behavior, and inattention. Baicalin exerts its effect in a dose-dependent manner, and high-dose baicalin has the most significant effect, but compared with MPH, it needs a longer time to play its therapeutic effect.
About author:: 10.7499/j.issn.1008-8830.2017.08.016
Cite this article:
ZHOU Rong-Yi,HAN Xin-Min,WANG Jiao-Jiao et al. Effect of baicalin on behavioral characteristics of rats with attention deficit hyperactivity disorder[J]. CJCP, 2017, 19(8): 930-937.
ZHOU Rong-Yi,HAN Xin-Min,WANG Jiao-Jiao et al. Effect of baicalin on behavioral characteristics of rats with attention deficit hyperactivity disorder[J]. CJCP, 2017, 19(8): 930-937.
Thomas R, Sanders S, Doust J, et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis[J]. Pediatrics, 2015, 135 (4): e994-e1001.
[2]
Antle MC, van Diepen HC, Deboer T, et al. Methylphenidate modifies the motion of the circadian clock[J]. Neuropsychopharmacology, 2012, 37 (11): 2446-2455.
[3]
Swanson JM, Kinsbourne M, Nigg J, et al. Etiologic subtypes of attention deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis[J]. Neuropsychol Rev, 2007, 17 (1): 39-59.
[4]
McCarthy S, Wilton L, Murray ML, et al. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care[J]. BMC Pediatr, 2012, 12: 78.
[5]
Gürkan K, Bilgiç A, Türkoglu S, et al. Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment[J]. J Psychopharmacol, 2010, 24 (12): 1810-1818.
[6]
Charach A, Fernandez R. Enhancing ADHD medication adherence: challenges and opportunities[J]. Curr Psychiatry Rep, 2013, 15 (7): 371.
[7]
Wang X, Zhang L, Hua L, et al. Effect of flavonoids in scutellariae radix on depression-like behavior and brain rewards: possible in dopamine system[J]. Tsinghua Sci Technol, 2010, 15 (4): 460-466.
Cheng O, Li Z, Han Y, et al. Baicalin improved the spatial learning ability of global ischemia/ reperfusion rats by reducing hippocampal apoptosis[J]. Brain Res, 2012, 1470: 111-118.
[10]
Chen L, Zhang L, Wang X, et al. Determination of dopamine and its relativity of baicalin in rat nuclei after intravenous administration of flavonoids from Scutellariae radix[J]. Biomed Chromatogr, 2007, 21 (1): 84-88.
[11]
Zhou R, Han X, Wang J, et al. Baicalin may have a therapeutic effect in attention deficit hyperactivity disorder[J]. Med Hypotheses, 2015, 85 (6): 761-764.
[12]
Cao AH, Yu L, Wang YW, et al. Effects of methylphenidate on attentional set-shifting in a genetic model of attention-deficit/hyperactivity disorder[J]. Behav Brain Funct, 2012, 8 (1): 10.
[13]
Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats[J]. Jpn Circ J, 1963, 27: 282-293.
[14]
Liu YF, Gao F, Li XW, et al. The anticonvulsant and neuroprotective effects of baicalin on pilocarpine-induced epileptic model in rats[J]. Neurochem Res, 2012, 37 (8): 1670-1680.
[15]
Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited[J]. FASEB J, 2008, 22 (3): 659-661.
[16]
Vorhees CV, Williams MT. Value of water mazes for assessing spatial and egocentric learning and memory in rodent basic research and regulatory studies[J]. Neurotoxicol Teratol, 2014, 45: 75-90.
[17]
Liu LL, Yang J, Lei GF, et al. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat[J]. Basic Clin Pharmacol Toxicol, 2008, 102 (6): 527-532.
[18]
Yang MT, Lu DH, Chen JC, et al. Inhibition of hyperactivity and impulsivity by carbonic anhydrase inhibitors in spontaneously hypertensive rats, an animal model of ADHD[J]. Psychopharmacology (Berl), 2015, 232 (20): 3763-3772.
[19]
Majdak P, Bucko PJ, Holloway AL, et al. Behavioral and pharmacological evaluation of a selectively bred mouse model of home cage hyperactivity[J]. Behav Genet, 2014, 44 (5): 516-534.
[20]
Liu LL, Yang J, Lei GF, et al. Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat[J]. Basic Clin Pharmacol Toxicol, 2008, 102 (6): 527-532.
[21]
Hong Q, Wang YP, Zhang M, et al. Homer expression in the hippocampus of an animal model of attention-deficit/hyperactivity disorder[J]. Mol Med Rep, 2011, 4 (4): 705-712.
Caballero-Puntiverio M, Fitzpatrick CM, Woldbye DP, et al. Effects of amphetamine and methylphenidate on attentional performance and impulsivity in the mouse 5-Choice Serial Reaction Time Task[J]. J Psychopharmacol, 2017, 31 (2): 272-283.
